DnaK Therapeutics
01 / DnaK TherapeuticsPreclinical · Tampa, Florida

Chemotherapy stops working. The reason may not be the cancer.

We are building the drug that blocks the protein, and the test that finds who needs it. Tumor-associated bacteria release a protein that shuts down p53, and cisplatin and 5-FU depend on p53 to work.

Cancer cells still alive after treatment Lower is better. A lower bar means the chemotherapy killed more cancer cells.

HCT116 human colorectal cell line

Cisplatin alone 31%
Cisplatin + bacterial DnaK 53%

AGS human gastric cell line

Cisplatin alone 40%
Cisplatin + bacterial DnaK 57%

Mouse primary tumor cells these cells make bacterial DnaK themselves

Cisplatin + bacterial DnaK 60%
Cisplatin + a DnaK inhibitor 45%

Trypan blue viability assay, 48 hours after treatment. Bacterial DnaK raised the share of cells surviving cisplatin in both human cell lines. In tumor cells that already carry DnaK, adding a DnaK-binding peptide brought survival back down. Cell-culture and animal data; no DnaK Therapeutics candidate has been tested in humans. Benedetti et al., Journal of Translational Medicine, 2024. 10.1186/s12967-024-05078-x

2024Company founded
2011Research begins, IHV
10Peer-reviewed papers
three of them in PNAS
25%Better anti-cancer effect
in published cell studies
02 / The problemWhy chemotherapy stops working

Resistance gets blamed on the tumor. Some of it is not the tumor.

Chemotherapy is central to treating the aerodigestive cancers and prostate cancer. In many patients it stops working. The usual explanation is that the tumor's own genetics shift under treatment. That does happen.

Our founders spent fifteen years on a different part of the answer. It turns out not to be human at all.

Take p53 away and the drugs lose their leverage.

03 / The mechanismFive steps
01

Bacteria live in the tumor

Fusobacterium nucleatum, Helicobacter pylori and several Mycoplasma species are found in and around tumors through the digestive tract and beyond.

02

They release DnaK

DnaK is a chaperone protein. Almost every bacterium has one. In these three the sequence is nearly identical to each other and clearly different from everyone else's.

03

p53 drops

Bacterial DnaK lowers p53, the protein that stops a damaged cell dividing. It also obstructs DNA repair, and it can cause genetic damage on its own.

04

The drugs lose their grip

Cisplatin and 5-FU need working p53 to finish the job. Without enough of it they do less.

05

Block DnaK and p53 comes back

Inhibiting the bacterial protein is intended to restore p53, and with it the effect of the chemotherapy a patient is already receiving.

Findings to date are from cell-culture and animal studies. No DnaK Therapeutics candidate has been tested in humans. The evidence, paper by paper.

04 / What we are buildingTwo programs

A therapeutic

Small molecules that inhibit bacterial DnaK, given alongside the chemotherapy a patient is already receiving, not instead of it. The aim is to bring back sensitivity to drugs that are already standard of care.

Pipeline →

A companion diagnostic

A test that measures how much bacterial DnaK a patient carries. A drug aimed at a bacterial protein only helps people who have the protein, so the test decides who the therapeutic is for.

Pipeline →

05 / Where the work comes fromProvenance
Originated atThe Institute of Human Virology, University of Maryland, Baltimore
LicensedBy technology transfer from the University of Maryland, Baltimore, in 2024
Based atUSF CONNECT, the Tampa Bay Technology Incubator
Funded in part byA 2025 research award from the Casey DeSantis Florida Cancer Innovation Fund, Florida Department of Health
Partnered withGATC Health, screening candidate molecules with predictive AI
Published inTen peer-reviewed papers between 2018 and 2026